-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Announces FDA Acceptance of Submission to Add PH-ILD to YUTREPIA Label
-
-
-
-
-
-
-
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent
-
-
-
-
-
-
-
Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
-
-
-
-
12,286 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All